Shilpa Medicare (NSE:SHILPAMED) Long-Term Debt: ₹1,838 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHILPAMED Shilpa Medicare Ltd NSE:SHILPAMED
76 GF Score
Price ₹603.60
GF Value ₹388.20
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shilpa Medicare Long-Term Debt?

Shilpa Medicare NSE:SHILPAMED -1.59% 76 Long-Term Debt is ₹1,838 Mil as of Mar. 2026. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 76/100 and a GF Value™ of ₹388.20 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Shilpa Medicare's Long-Term Debt for the quarter that ended in Mar. 2026 was ₹1,838 Mil.

Shilpa Medicare's quarterly Long-Term Debt declined from Sep. 2025 (₹1,896 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹1,838 Mil).

Shilpa Medicare's annual Long-Term Debt declined from Mar. 2024 (₹5,602 Mil) to Mar. 2025 (₹2,320 Mil) and declined from Mar. 2025 (₹2,320 Mil) to Mar. 2026 (₹1,838 Mil).

Shilpa Medicare  (NSE:SHILPAMED) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Shilpa Medicare Long-Term Debt Related Terms

Shilpa Medicare Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Shilpa Medicare's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shilpa Medicare Long-Term Debt Chart

Shilpa Medicare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,536.02 2,888.19 5,601.60 2,319.57 1,838.10

Shilpa Medicare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,319.57 0.00 1,895.89 0.00 1,838.10
NSE:SHILPAMED
76GF Score
Shilpa Medicare Ltd NSE:SHILPAMED
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹1,838 Mil mean?
Shilpa Medicare (NSE:SHILPAMED) has a Long-Term Debt of ₹1,838 Mil as of Mar. 2026.
Is Shilpa Medicare's Long-Term Debt too high?
Shilpa Medicare's current Long-Term Debt is ₹1,838 Mil. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Long-Term Debt compare to ZTS and UTHR?
Shilpa Medicare's Long-Term Debt of ₹1,838 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Shilpa Medicare's current Long-Term Debt is ₹1,838 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹388.20, compared to a current price of ₹603.60 — trading 55.5% above its estimated fair value. The current Long-Term Debt is ₹1,838 Mil. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current Long-Term Debt is ₹1,838 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?

Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued. The current stock price of ₹603.60 is trading 55.5% above its estimated GF Value™ of ₹388.20. GuruFocus considers Shilpa Medicare to be Significantly Overvalued.

Key valuation signals for NSE:SHILPAMED:

  • Long-Term Debt: ₹1,838 Mil
  • GF Value™: ₹388.20 vs. price of ₹603.60 (55.5% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shilpa Medicare Business Description

Other Exchanges 530549:India
Address Hyderabad Road, No. 12-6-214/A-1, Shilpa House, Raichur, KA, IND, 584135
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score

Get the complete analysis for NSE:SHILPAMED

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹603.60
Price
₹388.20
GF Value